What Is Actinium?

Actinium is a radioactive metallic element with atomic number 89, the first member of the actinide series in the periodic table. It was discovered in 1899 by the French chemist André-Louis Debierne in uranium ore residues left after Marie Curie had extracted radium, and it was independently identified by Friedrich Giesel in 1902. Actinium is intensely radioactive: in the dark it emits a pale blue glow caused by its ionizing radiation exciting the surrounding air. Natural actinium occurs only in trace quantities in uranium and thorium ores as a product of radioactive decay chains, so the amounts available for practical use are produced artificially through nuclear reactions. Its most technologically significant isotope, actinium-225, has become the focus of active research in nuclear medicine because of its favorable decay properties for cancer therapy.

Physical and Chemical Properties

Actinium is a silvery-white metal that belongs to Group 3 of the periodic table, and its chemistry is dominated by the +3 oxidation state. In aqueous solution it forms Ac³⁺ ions that behave similarly to the trivalent lanthanide ions but with a somewhat larger ionic radius, a distinction that influences which chelating agents can bind it effectively. Actinium reacts with oxygen to form actinium oxide (Ac₂O₃), which forms a protective surface layer. Its first ionization energy and coordination chemistry are of active scientific interest because the actinium ion is challenging to study: even in macroscopic quantities it is sufficiently radioactive that standard laboratory handling requires radiological containment, making precise coordination-chemistry measurements difficult. At room temperature actinium adopts a face-centered cubic crystal structure, similar to the heavier lanthanides.

Nuclear Decay and Isotopes

Actinium has no stable isotopes; all are radioactive. The longest-lived is actinium-227, with a half-life of 21.77 years, which decays primarily by beta emission to thorium-227, and by a small fraction of alpha decay to francium-223. Actinium-225, with a half-life of approximately 10 days, undergoes alpha decay to francium-221 and subsequently produces a cascade of four net alpha particles through its decay chain before reaching stable bismuth-209. This cascade is the source of its therapeutic value. Actinium-225 is produced in two principal ways: by separation from stored thorium-229 in a process called "milking," practiced at national laboratories such as Oak Ridge National Laboratory, and by accelerator-based production in which high-energy protons irradiate thorium-232 targets. As described by the National Isotope Development Center at the U.S. Department of Energy, a tri-laboratory accelerator program involving Brookhaven, Los Alamos, and Oak Ridge was established in 2015 to scale up actinium-225 supply for clinical research.

Targeted Alpha Therapy

The primary technological application of actinium today is in targeted alpha therapy (TAT) for oncology. In TAT, actinium-225 is conjugated to a targeting molecule, typically a monoclonal antibody or a small peptide, that binds selectively to antigens expressed on tumor cells. Once delivered to the tumor site, the isotope's alpha-emitting decay cascade deposits dense ionizing radiation within a range of only a few cell diameters, causing irreparable double-strand DNA breaks while limiting dose to surrounding healthy tissue. A review in PMC on actinium-225 in targeted alpha therapy surveys clinical trials underway for prostate cancer, acute myeloid leukemia, neuroendocrine tumors, and breast cancer. Accurate dosimetry requires a radioactivity standard, and the NIST program for actinium-225 calibration established reference measurements to support FDA review of actinium-based radiopharmaceuticals.

Applications

Actinium has applications in several scientific and medical domains, including:

• Targeted alpha therapy for treating prostate cancer, acute myeloid leukemia, and neuroendocrine tumors
• Neutron source applications when combined with beryllium to produce neutron beams for research
• Radiotracer studies of actinide chemistry and coordination behavior in the environment
• Nuclear waste research, where actinium behavior in geological repositories is modeled as part of uranium decay chain analysis